Log in to save to my catalogue

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in h...

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in h...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5478408

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial

About this item

Full title

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial

Publisher

Canada: Joule Inc

Journal title

Canadian Medical Association journal (CMAJ), 2017-06, Vol.189 (24), p.E819-E827

Language

English

Formats

Publication information

Publisher

Canada: Joule Inc

More information

Scope and Contents

Contents

The 2013-2016 Ebola virus outbreak in West Africa was the most widespread in history. In response, alive attenuated recombinant vesicular stomatitis virus (rVSV) vaccine expressing
glycoprotein (rVSVΔG-ZEBOV-GP) was evaluated in humans.
In a phase 1, randomized, dose-ranging, observer-blind, placebo-controlled trial, healthy adults aged 18-65...

Alternative Titles

Full title

Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5478408

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5478408

Other Identifiers

ISSN

0820-3946

E-ISSN

1488-2329

DOI

10.1503/cmaj.170074

How to access this item